How herbal medicines are being used for medicinal purposes in Africa is one of the most promising advances in decades, and one that’s been hailed as a potential boon for millions of people suffering from skin cancers.
Now, researchers from Harvard University and Yale University have identified a new class of herb extracts that are capable of healing and preventing skin cancers, and they’re also being tested for their potential as a treatment for other conditions.
The discovery is a major step in the development of treatments that can fight and even prevent skin cancers that can be caused by infection, infection-related inflammation, or inflammation-related tumors.
For instance, the study, published in the Proceedings of the National Academy of Sciences, identified a compound in the extract called aorticosterone, which acts as a vasodilator and a painkiller.
It’s the first compound that has been identified that can treat skin cancers by blocking the production of a molecule called the receptor for painkiller receptors.
That compound is also known as aortocanidin, or anandamide, which also acts as painkiller and vasodilation receptor blockers.
“We have identified an important molecule that binds to the receptor and blocks the production and release of a pain killer,” says Jyoti Bhavsar, the lead author of the study and a researcher at Harvard’s School of Public Health.
The compound binds to a receptor on the surface of a protein called A1R.
When A1Rs are blocked, A1 receptors in the body become less sensitive to pain.
The study also showed that the compound binds selectively to A1 and A2 receptors, and this compound acts as an analgesic for both A1s and A1 R.
The research was led by Bhavsgari and Dr. Yves Roeser, who is the senior author of both papers.
The results are a major advance in the field of treating skin cancers caused by infections, inflammation, and tumors that are caused by inflammatory cells that come from other organs.
“What we found is that aorto-antecedent effects are mediated through the activation of a receptor-dependent mechanism that is critical for the survival of the cancer cell,” Bhavsdars says.
“It seems to have been an interesting mechanism to look at.”
The research also found that a chemical called oleuropein is another compound that binds selectively and blocks A1A receptors.
That compound, which is also called aetylspermine, also acts like a vasoconstrictor.
The research team is now studying how the compound can be used to treat cancer-related pain.
The study was conducted with a team of scientists at Harvard Medical School, Yale University, the University of Alabama at Birmingham, and the National Institutes of Health.
It was funded by the National Science Foundation and the Department of Defense Advanced Research Projects Agency.
The information was provided by the Harvard Health Service, the National Cancer Institute, the Department in Charge of Biomedical Research at the National Institute of Environmental Health Sciences, the Harvard Medical Center, and Harvard Medical Schools.